Significance of ERCC1 and Hormonal Receptor Expression in Ovarian Cancer

Dalia Abd El-moniem Elrawi¹, Ahmed Ibrahim El khodary², Hanan Ramadan Nassar³, Amira Diyaa Darwish³, and Eman Naguib Khorsheed⁴

¹Department of Medical Oncology, Ahmed Maher Teaching Hospital, Cairo, Egypt, ²Department of medical oncology, NCI, Cairo University, Cairo, Egypt, ³Department of Pathology, NCI, Cairo University, Cairo, Egypt

Abstract: Background & Objectives: Ovarian carcinoma usually has a relatively poor prognosis. A rational approach to identify patients, who are likely to benefit from therapy, is urgently needed. Excision repair cross-complementation group 1 enzyme (ERCC1) has been proposed as a molecular predictor of clinical resistance to platinum-based chemotherapy. Steroid hormone receptors are important determinants of prognosis and predictive behavior in tumor tissues of several origins. The present study aimed to investigate the expression profile of ERCC1, ER & AR in patients with ovarian carcinoma and their association with patient outcome. Methods: This is a prospective study which included 77 patients with ovarian carcinoma who were treated with platinum based chemotherapy at the National Cancer Institute (NCI) in Egypt during the period 7/2016- 7/2018. We evaluated the expression of ER, AR, and Excision repair cross-complementation group 1 enzyme (ERCC1) by immunohistochemistry. Expression profiles were compared to clinical, histologic and prognostic factors, the clinical outcome and survival. All patients received platinum containing chemotherapy regimen. Results: Of the 77 patients with ovarian cancer, 66.2% (51/77) were ERCC1-positive, 49.4% (38/77) were AR positive & 75.3% (58/77) were ER positive. Platinum resistance was found in eight of the tumors with positive ERCC1 protein expression compared with two among the patients with negative tumor staining for ERCC1 (P = 0.643). There was significant association between ER & AR expression and pathological subtypes (p = 0.004, 0.007) respectively. There were no significant association between ER, AR & ERCC1 expression and PFS (P = 0.447, P = 0.162, P = 0.508 respectively) or OS (P = 0.781, P = 0.569, P = 0.381 respectively). Based on Cox proportional hazards regression analysis ERCC1, ER & AR were not independent factors affecting the prognosis of patients with ovarian carcinoma. Conclusion: These results demonstrate that positive ERCC1 expression is not associated with clinical resistance to platinum-based chemotherapy, ERCC1, AR & ER expression are not independent factors affecting the prognosis of patients with epithelial ovarian tumors and not associated with survival benefits. J. Med. Invest. 67: 391-398, August, 2020

Keywords: Excision repair cross-complementation (ERCC1) expression, ER & AR expression, Ovarian cancer, Platinum-resistance, Survival

INTRODUCTION

Ovarian cancer is the leading cause of gynecologic cancer death in the United States. Ovarian cancer accounting for 3% of cancers among women in the United States, but is the fifth most common cause of cancer-related death. It was estimated that approximately 22,280 women were diagnosed with ovarian cancer in the United States in 2018, and that approximately 14,070 women died as a result of ovarian cancer in 2018 (1). According to the National Population-Based Registry Program of Egypt 2008-2011, ovarian cancer represent 4.12% with crude rate 4.6. It is the 4th most common cancer in females. There is a progressive increase in number of incident ovarian cancer cases from 2288 in 2013 to 5957 in 2050, approximately 260% of 2013 incidence. Proportion of ovarian cancer was highest in upper Egypt (6.1%), and almost similar in middle Egypt (3.8%), and lower Egypt (3.9%) (2).

Platinum-based chemotherapy drugs are first-line treatments for ovarian cancer (3). However, a large number of patients do not respond to platinum-based chemotherapy due to drug resistance.

Previous research shows that the nucleotide excision repair (NER) system plays an important role in platinum resistance to chemotherapy (4). It repairs platinum-induced DNA damage by removing the damaged fragments in the DNA molecule, and then synthesizing DNA by DNA polymerase. ERCC1 (excision repair cross complementation group 1) is a key gene involved in NER.

Endocrine factors play key roles in ovarian cancer development, with risk reduction related to multiparity and use of oral contraceptives (5,6).

Estrogen regulates growth and differentiation in the normal ovaries and has been demonstrated to have mutagenic effects. Progesterone, on the other hand, induces apoptosis and decreases cell membrane permeability, leading to decreased invasive potential (7). After menopause, when the estradiol level decreases, androgens are still produced and also seem to influence ovarian cancer development. Androgens promote cell proliferation, and androgen levels are decreased by the use of oral contraceptives (8).

The present study aimed to investigate the following:

1-Prognostic value of immunohistochemical expression of

Abbreviations
AR: Androgen Receptor; EOC: Epithelial Ovarian Cancer; OCSS: Ovarian Cancer Specific Survival; ERCC1: Excision repair cross-complementation group 1; IHC: Immunohistochemistry; ER: Estrogen Receptor; NER: nucleotide excision repair, PFS: progression-free survival, OS: Overall survival, HR: Hormonal Receptors

Received for publication January 19, 2020; accepted March 10, 2020. Address correspondence and reprint requests to Dalia Elrawi, 151 Emtedad Ramsis 2, Nasr City, Cairo, Egypt.

The Journal of Medical Investigation    Vol. 67 2020
ERCC1 and Sex steroid hormone receptors in the tumor tissue as regards progression free survival and overall survival.

2-Predictive value of ERCC1 expression as regards response to platinum-based therapy.

MATERIALS AND METHODS

Patients

A total of 77 patients diagnosed with EOC were recruited between July 2016 and July 2018 in National Cancer Institute (Egypt). The median age at diagnosis was 53 years, ranged between 18–74 years. As presented in (Table 1), The tumors were classified according to the International Federation of Gynecology and Obstetrics classification system, with 16 (20.8%) samples classified as stage IA, 9 (11.7%) as stage IB, 8 (10.4%) as stage II, 19 (24.7%) as stage III and 25 (32.5%) as stage IV. The pathological types of the tumor samples were as follows : 56 (72.7%) Serous carcinoma samples (9 low G (G1), 7 intermediate (G2), 40 high G (G3), 5 (6.5%) mucinous carcinoma, 12 (15.6%) endometrium cancer and 2 clear cell carcinoma, 2 transitional carcinoma. 67 (87%). Optimal radical surgery (PAH-BSO) was done in 67 patients (87%), while conservative surgery was done for 9 patients (11.6%) including 7 patients unilateral salpingooophrectomy (9%), 2 patients excised ovarian mass. Peritoneal biopsy was performed in 1 patients.

66 patients (85.7%) received systemic platinum-based combination chemotherapy, following the surgical procedure, 37 (56.06%) patients received systemic chemotherapy as adjuvant treatment, 14 (21.21%) received as neo-adjuvant and 15 (22.7%) patients received systemic chemotherapy as adjuvant and neoadjuvant.

48 patients (72.2%) received 6 courses of chemotherapy or more.

Chemotherapy regimens consisted of 175 mg/m² taxol plus carboplatin calculated at AUC 5–6 every 3 weeks for 6–8 cycles or cycle every week for 18 weeks with AUC 2-3.

Most of patients (n = 37) (57.8%) received carboplatin with AUC 5-6 every 3 weeks and 27 (42.2%) patients received carboplatin weekly with AUC 2-3.

Ethical approval for the study was granted by the Cairo University ethics committee (Egypt), and all patients had given their written informed consent to participate in the study.

Immunohistochemical analysis

Tumor specimens were harvested from 77 patients prior to receiving platinum-based treatment.

1. Paraffin sections were made at 4 microns thickness and mounted on positive charged slides.

2. Immunostaining was done for all cases using Automated BenchMark ULTRA IHC/ISH system, and the following steps occurred automatically:

  • Post counter staining with bluing reagent for 4 minutes.
  • Counterstaining with Hematoxylin II for 8 minutes.
  • Application of Diaminobenzidine (DAB) as a chromogen applied.

3. Slides were washed in tap water and soap for 5 minutes and then dehydrated in the ascending grades of alcohol for 5 minutes.

4. Slides were washed in tap water and soap for 5 minutes and then dehydrated in the ascending grades of alcohol for 5 minutes in each container.

5. Slides were cleared in Xylene, and then cover slips were applied.

Chemotherapy outcome

Clinical curative effect was assessed by routine gynecological examination, imaging analysis (color ultrasound, computed tomography, magnetic resonance imaging or positron emission tomography-computed tomography for abdominal or pelvic regions) and detection of serum carbohydrate antigen (CA)-125 levels. No recurrence at 6 months post-chemotherapy was referred to as ‘clinically sensitive’ and included normal serum CA-125 levels, no new lesions, or the original residual lesions

Table 1. Clinicopathological data of 77 patients with EOC

| Characteristics | Numbers | Percentage | Valid percent |
|----------------|---------|------------|--------------|
| **Age** |
| ≤ 55 | 42 | 54.5 |
| > 55 | 35 | 45.5 |
| **SA (n = 63)** |
| < 1.8 | 28 | 36.4 |
| > 1.8 | 35 | 45.5 |
| **BMI (n = 62)** |
| < 30 | 26 | 33.8 |
| ≥ 30 | 36 | 46.8 |
| **CA 125 (n = 67)** |
| < 53 | 42 | 54.5 |
| > 53 | 25 | 31.2 |
| **Stage** |
| IA | 16 | 20.8 |
| IB | 9 | 11.7 |
| II | 8 | 10.4 |
| III | 19 | 24.7 |
| IV | 25 | 32.5 |
| I, II | 33 | 42.9 |
| III, IV | 44 | 57.1 |
| **Malignant ascites** |
| present | 28 | 36.4 |
| **Peritoneal implants** |
| present | 24 | 31.2 |
| **Omentum deposits** |
| present | 25 | 32.5 |
| **Distant metastasis** |
| Pleural effusion (M1a) | 5 | 6.5 |
| Liver (HFLs) | 10 | 13.0 |
| Pulmonary nodules | 4 | 5.2 |
| Spleen focal lesions | 4 | 5.2 |
| Anterior abdominal wall | 2 | 2.6 |
| Non regional LNs | 13 | 16.9 |
| **Histopathology** |
| Serous | 56 | 72.7 |
| Endometrioid | 12 | 15.6 |
| mucinous | 5 | 6.5 |
| others | 4 | 5.2 |
| **Grades** |
| I | 12 | 15.6 |
| II | 19 | 24.7 |
| III | 46 | 59.7 |
| **ERCC1** |
| N | 26 | 33.8 |
| P | 51 | 66.2 |
| **ER** |
| N | 19 | 24.7 |
| P | 58 | 75.3 |
| **AR** |
| N | 39 | 50.6 |
| P | 38 | 49.4 |

SA : Surface area, BMI : Body mass index, ER : Estrogen receptor, AR : Androgen receptor, ERCC1 : Excision repair cross-complementation group 1
had decreased in size or disappeared as identified by pelvic and imaging examination. By contrast, disease progression during chemotherapy, a continual increase in serum CA-125 levels or the appearance of new lesions identified by imaging at 6 months post-chemotherapy was recognized as ‘clinical resistance’.

Follow-up

The final follow-up occurred on July 2019. The median follow up period was 22.8 months (range, 1.4 – 38.5 months). Disease PFS was described as the time from ovarian cancer surgery or the time from start neoadjuvant chemotherapy to disease recurrence or mortality, whichever came first. The time between surgery or start treatment and mortality or the end of follow-up was described as the overall survival time (OS).

Statistical analysis

Statistical analysis was done using IBM SPSS® Statistics version 22 (IBM® Corp., Armonk, NY, USA). Numerical data were expressed as mean and standard deviation or median and range as appropriate. Qualitative data were expressed as frequency and percentage. Pearson’s Chi-square test or Fisher’s exact test was used to examine the relation between qualitative variables. For not normally distributed quantitative data, comparison between two groups was done using Mann-Whitney test (non parametric t-test). Survival analysis was done using Kaplan-Meier method and comparison between two survival curves was done using log-rank test. Multivariate analysis was done using Cox-regression method for the factors affecting survival on univariate analysis. Hazard ratio (HR) with its 95% confidence interval (CI) were used for risk estimation. All tests were two-tailed. A p-value < 0.05 was considered significant.

RESULTS

Expression of ERCC1 and Relation to Outcome

Brown-yellow granules were observed in the majority of tumor cell cytoplasm and nuclei, and corresponded with positive ERCC1 expression (Fig. 1). Immunohistochemistry identified that 51/77 specimens (66.2%) were ERCC1 positive.

As presented in (Table 3), no significant association was identified between ERCC1 expression and age (P = 0.930), pathological type (P = 0.482), cell differentiation (P = 0.461), clinical stage (P = 0.316) and ER expression (P = 0.056) or AR expression (P = 0.127).

While there was significant association between ERCC1 expression and elevated serum level of CA 125 at the time of diagnosis (P = 0.046). Also, presence of omental deposits was significantly correlated with the positive ERCC1 expression in tumor tissue (P = 0.022).

As presented in (Table 4) (Fig.2), the number of resistant cases with positive ERCC1 expression (8/10; 80%) was not significantly greater than the number of sensitive cases with positive ERCC1 expression (41/63; 65.1%) (P = 0.351). For the 77 EOC cases, there

---

Table 2. List of used immunohistochemical markers

| Antibodies | Clone | Source | Incubation Temp | Incubation Time (min) | Visualization | Positive Control |
|------------|-------|--------|----------------|-----------------------|--------------|-----------------|
| AR (N-20)  | Sc-816 Rabbit polyclonal | Santa Cruz Biotechnology | 42°C | 32 | Nuclear | Prostatic carcinoma |
| ERCC-1     | 8F1   Mouse monoclonal | Gene Tex | 37°C | 32 | Nuclear | Tonsil |
| ER         | SP1   Rabbit monoclonal | Roche | 37°C | 36 | Nuclear | Breast |

Figure 1. Positive reaction to ERCC1 in almost all tumor cells, both cytoplasmic and nuclear (X10).

Table 3. Correlation between ERCC1 expression and clinical pathological features.

| Clinical feature | n | negative | positive | p-value |
|-----------------|---|----------|----------|---------|
| Age, years      |   |          |          |         |
| 53              | 42| 14       | 28       | 0.930   |
| > 53            | 35| 12       | 23       |         |
| Stage           |   |          |          | 0.316   |
| IA              | 16 | 9       | 7        |         |
| IB              | 9  | 3       | 6        |         |
| II              | 8  | 3       | 6        |         |
| III             | 19 | 5       | 14       |         |
| IV              | 25 | 7       | 18       |         |
| LII             | 33 | 14      | 19       |         |
| III, IV         | 44 | 12      | 32       |         |
| Pathological subtypes | | | | 0.482 |
| serous         | 56 | 20      | 36       |         |
| endometrioid   | 12 | 2       | 10       |         |
| mucinous       | 5  | 1       | 4        |         |
| Grade          |   |          |          | 0.461   |
| GI             | 12 | 5       | 7        |         |
| GII            | 19 | 8       | 11       |         |
| GIII           | 46 | 13      | 33       |         |
| ER             |   |          |          | 0.056   |
| negative       | 19 | 3       | 16       |         |
| positive       | 58 | 23      | 35       |         |
| AR             |   |          |          | 0.127   |
| negative       | 39 | 10      | 29       |         |
| positive       | 38 | 16      | 22       |         |
| CA 125         |   |          |          | 0.046   |
| < 35           | 12 | 1       | 11       |         |
| > 35           | 55 | 21      | 34       |         |
| Omentum        |   |          |          | 0.022   |
| absent         | 52 | 22      | 30       |         |
| present        | 25 | 4       | 21       |         |

ER : Estrogen receptor, AR : Androgen receptor, ERCC1 : Excision repair cross-complementation group 1
was no significant difference in PFS and median OS between patients with positive ERCC1 expression and patients with negative expression (OS, \( P = 0.381 \); PFS, \( P = 0.508 \)) (Fig. 3).

**Expression of Sex Steroid Hormone Receptors and Relation to Outcome**

The expression and the prognostic value were first assessed individually for each marker, with ER positivity detected in 58/77 (75.3%) (Fig 4) and AR positivity detected in 38/77 (49.4%) (Fig 5).

| Table 4. Correlation between ERCC1 expression and platinum sensitivity. |
|---|---|---|---|
| ERCC1 | Sensitive | Resist | P-value |
| N (n = 24)(32.9%) | 22 (34.9%) | 2 (20%) | 0.351 |
| P (n = 49)(67.1%) | 41 (65.1%) | 8 (80%) |

ERCC1 : Excision repair cross-complementation group 1

---

Figure 2. Correlation between ERCC1 expression and platinum sensitivity.

Figure 3. OS and PFS of patients with positive expression of ERCC1 vs. those with negative.

Figure 4. Moderate diffuse positive nuclear reaction to ER in most of tumor cells (X10).

Figure 5. Positive reaction to AR in some tumor cells (X10).
Expression of either ER or AR was not associated with improved PFS ($P = 0.447$, $P = 0.162$ respectively) (Fig 6) and OS ($P = 0.781$, $P = 0.569$ respectively) (Fig 7).

| Clinical feature               | n  | negative | positive | p-value |
|-------------------------------|----|----------|----------|---------|
| Age, years                    |    |          |          | 0.050   |
| <= 53                         | 42 | 17       | 25       |         |
| > 53                          | 35 | 22       | 13       |         |
| SA                            |    |          |          | 0.028   |
| < 1.8                         | 28 | 19       | 9        |         |
| >= 1.8                        | 35 | 14       | 21       |         |
| Stage                         |    |          |          | 0.236   |
| IA                            | 16 | 7        | 9        |         |
| IB                            | 9  | 4        | 5        |         |
| II                            | 8  | 2        | 6        |         |
| III                           | 19 | 9        | 10       |         |
| IV                            | 25 | 17       | 8        |         |
| I-II                          | 33 | 13       | 20       | 0.087   |
| I-IV                          | 44 | 26       | 18       |         |
| Pathological subtypes         |    |          |          | 0.318   |
| serous                        | 56 | 25       | 31       |         |
| endometrioid                  | 12 | 8        | 4        |         |
| mucinous                      | 5  | 3        | 2        |         |
| Grade                         |    |          |          | 0.795   |
| GI                            | 12 | 5        | 7        |         |
| GII                           | 19 | 10       | 9        |         |
| GIII                          | 46 | 24       | 22       |         |
| ER                            |    |          |          | 0.094   |
| negative                      | 19 | 15       | 4        |         |
| positive                      | 58 | 24       | 34       |         |
| ERCC1                         |    |          |          | 0.127   |
| negative                      | 26 | 10       | 16       |         |
| positive                      | 51 | 29       | 22       |         |

SA: Surface area, ER: Estrogen receptor, AR: Androgen receptor, ERCC1: Excision repair cross-complementation group 1

| Clinical feature               | n  | negative | positive | p-value |
|-------------------------------|----|----------|----------|---------|
| Age, years                    |    |          |          | 0.847   |
| <= 53                         | 42 | 10       | 32       |         |
| > 53                          | 35 | 9        | 26       |         |
| SA                            |    |          |          | 0.049   |
| < 1.8                         | 28 | 11       | 17       |         |
| >= 1.8                        | 35 | 6        | 29       |         |
| Stage                         |    |          |          | 0.815   |
| IA                            | 16 | 5        | 11       |         |
| IB                            | 9  | 2        | 7        |         |
| II                            | 8  | 1        | 7        |         |
| III                           | 19 | 6        | 13       |         |
| IV                            | 25 | 5        | 20       |         |
| I-II                          | 33 | 8        | 25       | 0.939   |
| III-IV                        | 44 | 11       | 33       |         |
| Pathological subtypes         |    |          |          | 0.007   |
| serous                        | 56 | 9        | 47       |         |
| endometrioid                  | 12 | 3        | 9        |         |
| mucinous                      | 5  | 4        | 1        |         |
| Grade                         |    |          |          | 0.867   |
| GI                            | 12 | 2        | 10       |         |
| GII                           | 19 | 5        | 14       |         |
| GIII                          | 46 | 12       | 34       |         |
| AR                            |    |          |          | 0.004   |
| negative                      | 39 | 15       | 24       |         |
| positive                      | 38 | 4        | 34       |         |
| ERCC1                         |    |          |          | 0.056   |
| negative                      | 26 | 3        | 23       |         |
| positive                      | 51 | 16       | 35       |         |

SA: Surface area, ER: Estrogen receptor, AR: Androgen receptor, ERCC1: Excision repair cross-complementation group 1

Figure 6. PFS of patients with positive expression of AR or ER vs. those with negative.

Figure 7. OS of patients with positive expression of AR or ER vs. those with negative.
ERCC1 expression, ER expression, AR expression, peritoneal deposits and platinum sensitivity. As presented in (Table 7), age, platinum sensitivity and received adjuvant chemotherapy were identified as independent factors significantly affecting the prognosis of patients (P = 0.048, P < 0.001 and P = 0.020, respectively), while other factors did not significantly affect prognosis.

Independent risk factors for patient survival time:

Cox proportional hazards regression was used to analyze possible risk factors, including age, histopathological type, degree of cancer cell differentiation, clinical stage, type of surgery and Cox regression analysis demonstrated that ERCC1 expression level, ER or AR expression were not an independent prognostic factor for the survival time of patients with EOC.

DISCUSSION

Chemotherapy drug resistance is a major factor restricting the improvement of patient survival rates, with 20–30% of patients with EOC undergoing primary platinum-resistance (9,10). With the rapid development of pharmacogenomics and molecular biology, the mechanism of cisplatin resistance is closely associated with NER (11). In DNA repair, ERCC1 is a key gene of the NER pathway due to its binding with DNA repair endonuclease ERCC1-xeroderma pigmentosum group F (XPF) (12,13).

A number of studies have examined the association between ERCC1 expression (14-18) and clinical outcomes including response to platinum-based therapy, PFS and OS in patients with EOC (19). The outcomes of these studies were discriminative, ranging from increased rate of platinum resistance (22), worse PFS and overall OS (20-22), similar PFS (23-26), to similar OS (20-23). In our current study, we were unable to confirm any statistically significant association between ERCC1 expression and resistance to platinum-based chemotherapy. PFS and OS did not significantly differ between the positive and negative ERCC1 expression.

A previous meta-analysis evaluated whether response to platinum-based chemotherapy was associated with ERCC1 expression in patients with ovarian cancer (24). It was observed that patients with negative ERCC1 expression had a significantly greater response to platinum-based chemotherapy compared with patients with positive ERCC1 expression (24), indicating that ERCC1 protein expression status is correlated with response to platinum-based chemotherapy in ovarian cancer. Zhao et al. (25) identified a negative correlation between ERCC1 expression and clinical chemosensitivity in EOC.

Stadlmann et al. analyzed 80 samples of ovarian cancer utilizing 8F-1 antibody for immunohistochemistry and found low overall ERCC1 expression (20.3%) and no association between protein expression and platinum responsiveness (p = 0.21) (16), which correlates with our results. In a study of Steffensen et al., immunohistochemistry with the 8F-1 antibody against ERCC1 was used to examine 100 tumor specimens: 45% of specimens were positive, which was associated with a significantly poorer response to platinum-based chemotherapy but not with a worse OS (15). Lin et al. corroborated these findings by demonstrating that low ERCC1 protein expression was significantly associated with drug sensitivity in 63 patients (26).

In a study of Rubatt et al. (27), in which patients who participated in GOG-172 and GOG-182 trials and provided tumor samples for translational research were included, 27% of tumors were ERCC1-positive. ERCC1 expression was not associated with clinical characteristics or platinum responsiveness. Women

Table 7. Univariate analysis for survival time.

|             | B   | SE  | Wald | df  | P-value | Exp (B) | 95% CI for Exp (B) |
|-------------|-----|-----|------|-----|---------|---------|--------------------|
| Age (years)| .305| .380|.923  | 1   | .337    | 1.440   | .684-3.031         |
| Stage(III, IV vs I,II)| .822| .419| 3.854| 1   | .050    | 2.276   | 1.001-5.172        |
| Surgery (other vs PAH+BSO)| .862| .462| 3.477| 1   | .062    | 2.368   | .957-5.861         |
| Histopathology| 1.413| 2   | .493 |      |         |         |                    |
| Path (serous vs mucinous)| .745| 1.022| .531 | 1   | .466    | 2.106   | .284-15.613        |
| Path (endometrod vs mucinous)| .137| 1.156| .014 | 1   | .905    | 1.147   | .119-11.054        |
| Grade| 2.330| 2   | .312 |      |         |         |                    |
| Grade(1 vs III)| -.1130| .746| 2.295| 1   | .130    | .323    | .075-1.394         |
| Grade(II vs III)| -.139| .444| .189 | 1   | .664    | .824    | .345-1.970         |
| Peritoneal involvement| 1.208| .406| 8.841| 1   | .003    | 3.347   | 1.509-7.420        |
| ERCC1 expression| .276| .419| .434 | 1   | .510    | 1.318   | .580-2.996         |
| ER,AR expression| 2.555| 2   | .279 |      |         |         |                    |
| ER,AR (either vs both +ve)| .603| .450| .019 | 1   | .889    | 1.065   | .440-2.575         |
| ER,AR (Both –ve vs both +ve)| .698| .466| 2.242| 1   | .134    | 2.011   | .806-5.017         |
| AR (-ve vs +ve)| .535| .387| 1.904| 1   | .168    | 1.707   | .799-3.646         |
| ER| .317| .419| .571 | 1   | .450    | 1.373   | .603-3.123         |
| Platinum sensitivity| 2.773| .471| 34.658| 1 | <0.001  | 16.005  | 6.358-40.290       |
| Adj,cth| .906| .388| 5.452| 1   | .020    | 2.475   | 1.157-5.297        |

CI: confidence interval; SE: standard error, df: degrees of freedom, ER: Estrogen receptor, AR: Androgen receptor, ERCC1: Excision repair cross-complementation group 1, PAH-BSO: Pan abdominal hysterectomy bilateral salpingoophorectomy
with ERCC1-positive versus negative tumors had similar median PFS (17.9 months versus 17.5 months, respectively, \( p = 0.59 \)), median OS (52 months versus 47 months, respectively, \( p = 0.30 \)), risk of disease progression (adjusted hazard ratio (HR) = 0.90, 95% CI = 0.71-1.15, \( p = 0.41 \)), and risk of death (adjusted HR = 0.81, 95% CI = 0.61-1.07, \( p = 0.14 \)).

However, Muallem et al. (28) demonstrated that there were no significant differences in the PFS between patients with low, intermediate and high H-scores for ERCC1 expression.

The prognostic value of sex steroid hormone receptor expression in ovarian cancer is not fully defined. In this study, we can however demonstrate that expression of ER and AR not predicts PFS and OS.

In the present study, no information on use of endocrine treatment was available, precluding analyses of possible effects of endocrine treatment on the findings reported. However, endocrine treatment is not standard in ovarian cancer and is unlikely to have been administered to the study cohort to such an extent that it has influenced the results (29,30).

The finding that aromatase inhibition appears slightly more effective than tamoxifen in ovarian cancer likely reflects the more efficient hormone inhibition of aromatase inhibitors. In support of this notion, epidemiological studies indicate that reduced circulating levels of androgens decrease the risk of developing ovarian cancer, but clinical studies have shown only limited effects of androgen deprivation (32,34,35).

The presence and prognostic value of AR expression in ovarian cancer vary in different studies, but increased AR expression seems to generally be associated with a favorable prognosis (29,31,33), contrary to the results in the present study.

Zhaojun, et al. (2017) who investigated the correlation between ER expression and epithelial ovarian cancer prognosis in thirty-five studies with a total of 5824 patients were included, and demonstrated that the expression of ER, especially ER \( \alpha \), was a positive predictor of overall survival among epithelial ovarian cancer patients (36), contrary to the results in the present study.

In conclusion, the present study demonstrated that high ERCC1 expression in patients with EOC was not associated with resistance to platinum-based chemotherapy or with survival time. In addition, it was also observed that ERCC1 protein expression was not an independent factor affecting the prognosis of patients. We demonstrate a prognostic role of PR and AR expression in ovarian cancer, with independent effects on PFS and OS and the best outcome for patients whose tumors displayed coexpression of ER and AR.

Further studies with larger sample sizes and improved study designs are required to investigate whether or not ERCC1 may function as a predictor for chemotherapy against EOC.

And our data define a basis for further evaluation of the role of sex steroid hormone receptors, and in the future possibly endocrine treatment, in ovarian cancer and support that such studies may be subtype specific to comprehensively evaluate the potential clinical benefit.

STATEMENT CONFLICT OF INTEREST

No conflict of interest.

REFERENCES

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2018. CA Cancer J Clin 68: 7-30, 2018

2. Amal SI, Hussein MK, Nabil NMH, Hoda B, Hosam K: Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program, Journal of Cancer Epidemiology, Volume 2014, Article ID 437971 : 18, https://doi.org/10.1155/2014/437971

3. Yan L, Pei H, Yu C, Gui-yang W, Na W, Rong-miao Z: Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis. Biomarkers 19(2) : 128-34, 2014

4. Gossage L, Madhusudan S: Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33(6): 565-77, 2007

5. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G: Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371: 303-314, 2008

6. Purdie DM, Bain Cj, Siskind V, Webb PM, Green AC: Ovulation and risk of epithelial ovarian cancer. Int J Cancer 104: 228-232, 2003

7. Ho SM: Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 1: 73, 2003

8. Coenen CM, Thomas CM, Born GF, Hollanders JM, Rolland R: Changes in androgens during treatment with four low-dose contraceptives. Contraception 53: 171-176, 1996

9. Lin H, Changchien CC: Management of relapsed/refractory epithelial ovarian cancer: Current standards and novel approaches. Taiwan J Obstet Gynecol 46: 379-388, 2007 doi : 10.1016/S1028-4559(08)60007-8.

10. Colombo N, Gore M: Treatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol 64: 129-138, 2007. doi : 10.1016/j.critrevonc.2007.04.004.

11. Althara R, Liang X, Yu JJ, Reed E: Excision repair cross complementing-group 1 Gene expression and platinum resistance. Int J Mol Med 14: 959-970, 2004

12. Andreieux LO, Fautrol A, Bessard A, Guillozo A, Baffet G, Langouët S: GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERR2 in human hepatoma cells. Cancer Res 67: 2114-2123, 2007. doi : 10.1158/0008-5472.CAN-06-3821.

13. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NG, Beverloo HB, Hoekmajers JH, Kanaar R: The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24: 5776-5787, 2004. doi : 10.1128/MCB.24.13.5776-5787.2004.

14. Steffensen KD, Waldstrom M, Jakobsen A: The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 19: 820-825, 2009

15. Steffensen KD, Waldstrom M, Jeppesen U, Brandtslund L, Jakobsen A: Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer 18: 702-710, 2008

16. Stadlmann S, Dirnhofer S, Guth U, Thies S, Singer G: ERCC1 immunexpression does not predict platinum-resistance in ovarian cancer. Gynecol Oncol 108: 252-253, 2008

17. Weberpals J, Garbuto K, O’Brien A, Clark-Knowles K, Doucette S, Antoniouk O, Goss G, Dimitroulakos J: The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 124: 806-815, 2009

18. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer.
cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703-708, 1994
19. Krivak TC, Darcy KM, Tian C, Bookman M, Gallion H, Ambrosone CB, Deloia JA : Single nucleotide polymorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced-stage ovarian and primary peritoneal carcinoma. A Gynecologic Oncology Group Study. Gynecol Oncol 122 : 121-126, 2011
20. Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA : Relationship between ERCC1 polymorphisms, disease progression, and survival in the gynecologic oncology group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 26 : 3598-3606, 2008
21. Smith S, Su D, Riquart de la Longris IA, Schwartz P, Pupello M, Rutherford TJ, Mor G, Yu H, Katsaros D : ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based chemotherapy. J Clin Oncol 25 : 5172-5179, 2007.
22. Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, Kang SB : Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds. A Korean population-based study. Gynecol Oncol 113 : 264-269, 2009
23. Marsh S, Paul J, King CR, Gifford G, Mcleod HL, Brown EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittomere AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ : Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14 : 853-862, 2013
24. Scottish randomised trial in ovarian cancer. J Clin Oncol 25 : 5172-5179, 2007.
25. dio : 10.1016/j.ygyno.2012.01.008.
26. Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, Deloia JA : Relationship between ERCC1 polymorphisms, disease progression, and survival in the gynecologic oncology group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 26 : 3598-3606, 2008
27. Marsh S, Paul J, King CR, Gifford G, Mcleod HL, Brown EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittomere AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ : Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14 : 853-862, 2013. doi : 10.1016/j.ygyno.2012.01.008.
28. Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, Deloia JA : Relationship between ERCC1 polymorphisms, disease progression, and survival in the gynecologic oncology group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 26 : 3598-3606, 2008
29. Lee P, Rosen DG, Zhu C, Silva EG, Liu J : Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 96 : 671-677, 2005
30. Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Hogfllall E, Deen S, Wentzensen N, Mysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkins LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Heggall C, Kallí KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bêhara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamín E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittomere AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ : Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14 : 853-862, 2013
31. Norin D, Zendebohrk N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, Jirström K : Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res 3 : 14, 2010
32. Elatta A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross P, Plummer ER, Robson CN, Edmonson RJ : Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol 124 : 142-147, 2012
33. Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, Castagna G : Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 17 : 231-237, 1998
34. Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Jasonos A, Sabbatini P : A phase II evaluation of goserelin mesilate for stage III epithelial ovarian cancer. J Clin Oncol 23 : 121-126, 2011
35. Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bêhara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamín E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittomere AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ : Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14 : 853-862, 2013
36. Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Jasonos A, Sabbatini P : A phase II evaluation of goserelin mesilate for stage III epithelial ovarian cancer. J Clin Oncol 23 : 121-126, 2011
37. Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, Castagna G : Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 17 : 231-237, 1998
38. Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Jasonos A, Sabbatini P : A phase II evaluation of goserelin mesilate for stage III epithelial ovarian cancer. J Clin Oncol 23 : 121-126, 2011
39. Elatta A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross P, Plummer ER, Robson CN, Edmonson RJ : Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol 124 : 142-147, 2012
40. Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Jasonos A, Sabbatini P : A phase II evaluation of goserelin mesilate for stage III epithelial ovarian cancer. J Clin Oncol 23 : 121-126, 2011
41. Elatta A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross P, Plummer ER, Robson CN, Edmonson RJ : Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol 124 : 142-147, 2012
42. Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Jasonos A, Sabbatini P : A phase II evaluation of goserelin mesilate for stage III epithelial ovarian cancer. J Clin Oncol 23 : 121-126, 2011
43. Elatta A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross P, Plummer ER, Robson CN, Edmonson RJ : Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol 124 : 142-147, 2012
44. Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Jasonos A, Sabbatini P : A phase II evaluation of goserelin mesilate for stage III epithelial ovarian cancer. J Clin Oncol 23 : 121-126, 2011
45. Elatta A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross P, Plummer ER, Robson CN, Edmonson RJ : Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol 124 : 142-147, 2012